RESEARCH NOTE

Performance of Lipoarabinomannan Assay using Cerebrospinal fluid for the diagnosis of Tuberculous meningitis among HIV patients [version 2; peer review: 2 approved]

Richard Kwizera, Fiona V. Cresswell, Gerald Mugumya, Micheal Okirwoth, Enock Kagimu, Ananta S. Bangdiwala, Darlisha A. Williams, Joshua Rhein, David R. Boulware, David B. Meya

Abstract

Background: The diagnostic utility of the Mycobacteria tuberculosis lipoarabinomannan (TB-LAM) antigen lateral flow assay on cerebrospinal fluid (CSF) for the diagnosis of tuberculous meningitis (TBM) has not been extensively studied and the few published studies have conflicting results.

Methods: Lumbar CSF from 59 HIV-positive patients with suspected TBM was tested with TB-LAM and Xpert MTB/Rif Ultra. The diagnostic performance of CSF TB-LAM was compared to positive CSF Xpert MTB/Rif Ultra (definite TBM) and a composite reference of probable or definite TBM according to the uniform case definition.

Results: Of 59 subjects, 12 (20%) had definite TBM and five (9%) had probable TBM. With reference to definite TBM, CSF TB-LAM assay had a diagnostic sensitivity of 33% and specificity of 96%. When compared to a composite reference of definite or probable TBM, the sensitivity was 24% and specificity was 95%. There were two false positive tests with TB-LAM (3+ grade). In-hospital mortality in CSF TB-LAM positive patients was 17% compared to 0% in those with definite TBM by Xpert MTB/Rif Ultra but negative LAM.

Conclusions: Lumbar CSF TB-LAM has a poor performance in diagnosing TBM. Both urine TB-LAM and Xpert Ultra should be further investigated in the diagnosis of TBM.

Keywords

Tuberculous meningitis, extra-pulmonary TB, lipoarabinomannan, TB-LAM, Xpert MTB/Rif Ultra, HIV, Diagnostics, cerebrospinal fluid
Corresponding author: Richard Kwizera (kwizerarichard@ymail.com)

Author roles: Kwizera R: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing; Cresswell FV: Conceptualization, Formal Analysis, Funding Acquisition, Methodology, Project Administration, Resources, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; Mugumya G: Formal Analysis, Investigation, Validation, Writing – Review & Editing; Okirwoth M: Formal Analysis, Investigation, Methodology, Writing – Review & Editing; Kagimu E: Data Curation, Investigation, Methodology, Writing – Review & Editing; Bangdiwala AS: Data Curation, Formal Analysis, Methodology, Validation, Writing – Review & Editing; Williams DA: Methodology, Project Administration, Resources, Supervision, Writing – Review & Editing; Rhein J: Project Administration, Resources, Supervision, Validation, Writing – Review & Editing; Meya DB: Funding Acquisition, Project Administration, Resources, Supervision, Validation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by the Wellcome Trust [107742, 107743 and 210772]. This research was also supported in part by the National Institute of Neurologic Diseases and Stroke (NINDS) and Fogarty International Center [R01NS086312, K01TW010268]. DBM and RK are currently supported through the DELTAS Africa Initiative grant [DEL-15-011] to THRiVE-2, from Wellcome Trust grant [107742] and the UK government. FVC is supported through a Wellcome Clinical PhD Fellowship [210772]. FVC is an honorary fellow of the Makerere University – UVRI Centre of Excellence for Infection and Immunity Research and Training (MUII-plus). MUII-plus is supported through the DELTAS Africa Initiative [107743]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS), Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa’s Development Planning and Coordinating Agency (NEPAD) with funding from the Wellcome Trust [107743] and the UK Government. The MRC/UVRI and LSHTM Uganda Research Unit is jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement and is also part of the EDCTP2 programme supported by the European Union.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2019 Kwizera R et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Kwizera R, Cresswell FV, Mugumya G et al. Performance of Lipoarabinomannan Assay using Cerebrospinal fluid for the diagnosis of Tuberculous meningitis among HIV patients [version 2; peer review: 2 approved] Wellcome Open Research 2019, 4:123 (https://doi.org/10.12688/wellcomeopenres.15389.2)

First published: 19 Aug 2019, 4:123 (https://doi.org/10.12688/wellcomeopenres.15389.1)
Amendments from Version 1

Based on the two reviewers’ comments to version 1, major changes were made to the conclusion and Table 1 while minor changes were made to the results section as seen in the tracked changes. We added the suggested reference in the discussion section. Table 1 was modified to present the characteristics of patients with diagnosis of definite, probable, possible and not-TBM. A sentence was added on cerebral imaging. We also added a sentence about the patients who were positive with urine LAM and those who were positive with urine Ultra. We added an explanation about the 17% of patients who had unknown outcome. A limitation was added that TB culture was not used. However, we have found Ultra to be more sensitive than culture (70% versus 43% against definite/probable) for the diagnosis of TBM in our population (Bahr, Lancet ID, 2018). In the conclusion section, we have mentioned the Fuji LAM that is a new LAM POC test that has higher sensitivity in urine than the determine LAM POC and should also be evaluated for diagnosis of TB meningitis both in urine and CSF. Lastly, based on the second reviewer’s comments, we would like to say that a cellular CSF is common in this population with advanced HIV disease even in the setting of a confirmed TB or CM infection (Cresswell, Int J Infect Dis 2018). The not-TBM group scored <6 points on the uniform case definition (n=16) or had a confirmed alternative diagnosis (n=10 with CM).

Any further responses from the reviewers can be found at the end of the article.

Introduction

In many human immunodeficiency virus (HIV) endemic countries, tuberculous meningitis (TBM) is the second most common cause of adult meningitis after cryptococcal meningitis, and accounts for 1–5% of all tuberculosis (TB) cases. TBM is the most severe form of TB and causes substantial morbidity and mortality in children and immunocompromised adults. HIV infection is known to increase the risk of death in patients with TBM, as does TB stage at the time of treatment initiation. As is the case in cryptococcosis, high-quality nursing care is a critical component in managing TBM patients.

Similarly, diagnosis of TBM is very challenging, especially in resource-limited settings where diagnosis relies on a combination of clinical, radiological and laboratory findings. The World Health Organisation (WHO) recommends Xpert MTB/RIF Ultra for the diagnosis of TBM using cerebrospinal fluid (CSF). Culture has many limitations related to turnaround time and sensitivity, and also requires considerable infrastructure and costs. Therefore, the development of early point of care diagnosis for TBM is a priority. Recent studies have demonstrated that the next generation Xpert MTB/RIF Ultra is the most sensitive diagnostic test in HIV-positive adults. However, Xpert MTB/RIF Ultra is not a bedside test, and thus access to same day results remain a challenge in many settings.

Assays based on the detection of mycobacterial lipoarabinomannan (TB-LAM) antigen in urine have emerged as potential point-of-care tests for extra-pulmonary TB. There is evidence that urine TB-LAM may help to reduce mortality and predict poor outcomes. The WHO recently added the TB-LAM assay onto its essential diagnostic list and recommended TB-LAM in hospitalised HIV positive adults with signs and symptoms of TB. However, there are conflicting results about TB-LAM assay sensitivity for TBM diagnosis in CSF. With reference to definite TBM, Cox et al. found a 75% sensitivity using CSF from the fourth ventricle in an autopsy cohort from 91 HIV-infected adults. However, Bahr et al. had no positive TB-LAM tests using lumbar CSF from 67 HIV patients with meningitis. In light of these results, and now that Xpert MTB/RIF Ultra is used instead of Xpert MTB/RIF, we aimed to further explore the utility of CSF TB-LAM test for the diagnosis of TBM among HIV-positive adults presenting with suspected meningitis.

Methods

Study setting and participants

Between April 2018 and June 2019, we assessed and performed diagnostic lumbar punctures on HIV-positive patients admitted to Mulago National Referral Hospital with suspected meningitis in Kampala, Uganda. Screening for TB was performed cross-sectionally as part of the High Dose Rifampicin for Tuberculous Meningitis (RIFT) trial (ISRCTN registration number ISRCTN42218549, last updated 24/04/2018). Therefore, we did not calculate a sample size for the current study but included all participants that fit the screening criteria for the RIFT trial. All included participants were HIV-infected adults (≥18 years old) who provided written informed consent by participant or surrogate, with a suspected diagnosis of TB (meningitis symptoms, clinical signs of meningism). Demographic information and baseline characteristics for participants were collected through clinical reviews using customized meningitis screening case report forms approved by the relevant ethics committees (Mulago Hospital Research Ethics Committee, Uganda National Council of Science and Technology, and the University of Minnesota). Opening pressures for CSF were measured using a manometer, followed by standard microbiology analysis (CrAg, cell count, protein, glucose, lactate, culture).

Diagnostic tests

In addition to standard microbiology analysis, CSF was tested with TB-LAM (Alere, Massachusetts, USA), and the test strip interpreted as per manufacturer’s instructions. Briefly, the protective foil cover was removed from each test and the strip labelled with the participant’s number. Two drops (or 60μL) of CSF were added to the sample pad. The test was then read after 25 minutes under standard indoor lighting conditions. The reference card was used in interpretation of the results by holding it alongside the patient window. For positive results, purple/gray bars appeared in both the control window and the patient window of the strip. For negative results, one purple/gray bar appeared in the control window of the strip and no bar appeared in the patient window of the strip. If there was no bar
null
Table 1. Characteristics of the study population.

| Baseline characteristics                  | Overall (N=59) | Definite TBM (n=12) | Probable TBM (n=5) | Possible TBM (n=15) | Not-TBM (n=27) |
|-------------------------------------------|---------------|---------------------|-------------------|--------------------|---------------|
|                                           | N*            | Statistic           | N*               | Statistic          | N*            | Statistic          |
| Women, n (%)                              | 58            | 29 (50)             | 12                | 6 (50)             | 5             | 3 (60)             |
| Age in years, median (IQR)                | 58            | 33 (28-40)          | 12                | 29 (28-33)         | 5             | 26 (24-34)         |
| On ART, n (%)                             | 47            | 29 (62)             | 11                | 7 (63.6)           | 2             | 2 (100)            |
| Headache, n (%)                           | 57            | 46 (81)             | 12                | 10 (83.3)          | 5             | 4 (80)             |
| Duration of headache, median (IQR) days   | 45            | 14 (14-24)          | 10                | 7.5 (14-30)        | 4             | 14 (10.5-17.5)     |
| Glasgow Coma Scale score, mean (SD)       | 55            | 13 (2.6)            | 12                | 12.5 (2.9)         | 5             | 11.8 (2.4)         |
| CSF CrAg positive, n (%)                  | 58            | 10 (17)             | 12                | 0 (0)              | 5             | 0 (0)              |
| CSF Opening Pressure, median (IQR) mmH2o   | 45            | 200 (120-260)       | 7                 | 180 (70-240)       | 3             | 260 (95-400)       |
| Acellular CSF, n (%)                      | 55            | 36 (55)             | 11                | 3 (27.3)           | 5             | 1 (20)             |
| CSF WBC in those with CSF WBC pleocytosis, median (IQR) cells/μL | 55 | 160 (135-268) | 8 | 280 (162.5-575) | 4 | 173 (130-237.5) | 3 | 80 (35-160) | 4 | 145 (87.5-210) |
| CSF protein, median (IQR) mg/dL           | 52            | 57 (28-141)         | 11                | 184 (107-316)      | 5             | 158 (147-215)      |
| CSF glucose, median (IQR) mg/dL           | 32            | 65 (34-82)          | 7                 | 44 (19.8-61)       | 3             | 90 (68-108)        |
| CSF lactate, median (IQR) mmol/L          | 36            | 3.9 (2.2-9)         | 8                 | 9.7 (8.2-11.2)     | 4             | 9.2 (6.3-11.1)     |
| Status at discharge                       | 59            | 40 (68)             | 9                 | 11 (9-14)          | 4             | 14.5 (10-16.5)     |
| Alive, n (%)                              | 40 (68)       | 9 (15)              | 10                | 8 (66.7)           | 3             | 1 (8.3)            |
| Dead, n (%)                               | 2 (40)        | 1 (20)              | 2                 | 8 (53.3)           | 2             | 13.3 (3.3)         |
| Unknown, n (%)                            | 15            | 8 (53.3)            | 2                 | 5 (33.3)           | 22            | 81.5 (3.3)         |
| Alive, n (%)                              | 22            | 81.5 (3.3)          | 2                 | 7 (4.2)            | 2             | 11.1 (7.4)         |

Data presented are percentages (%), medians and interquartile ranges (IQR). N= number of participants with data for each parameter. * Participants with data available. ART = antiretroviral therapy, CSF = cerebrospinal fluid, WBC = white blood cells.

Table 2. Summary of diagnostic performance of cerebrospinal fluid mycobacterial lipoarabinomannan assay for tuberculous meningitis.

| Reference standard | Disease prevalence | Sensitivity | Specificity | PPV | NPV | Test Accuracy |
|--------------------|--------------------|-------------|-------------|-----|-----|---------------|
| Definite/probable TBM | 28.8% (17/59)       | 23.5%       | 95.2%       | 66.7% | 75.5% | 74.6% (44/59) |
| 95% CI             | 17.8 to 42.1%      | 6.8 to 49.9% | 83.8 to 99.4% | 28.7 to 90.8% | 70.1 to 80.2% | 61.6 to 85% |
| Definite TBM       | 20.3% (12/59)       | 33.3%       | 95.7%       | 66.7% | 84.9% | 83.1% (49/59) |
| 95% CI             | 10.9 to 32.8%      | 9.9 to 65.1% | 85.5 to 99.5% | 29.3 to 90.6% | 78.9 to 89.4% | 71 to 91.6% |

Data presented are the percentage, numerator/denominator, and 95% confidence intervals (CI). Test Accuracy = overall probability that a patient will be correctly classified. PPV = Positive predictive value, NPV = negative predictive value, TBM = tuberculous meningitis.

warrants evaluation for diagnosis of TB meningitis both in urine and CSF.

Data availability
Underlying data
Figshare: CSFLAM_data set revised.xlsx. https://doi.org/10.6084/m9.figshare.9415853.v1

Acknowledgements
We thank institutional support from the IDI research office.
References

1. Jarvis JN, Mintjes G, Williams A, et al.: Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis. 2010; 10: 67. PubMed Abstract | Publisher Full Text | Free Full Text

2. Thao LTP, Heemskerk AD, Geskus RB, et al.: Prognostic Models for 9-Month Mortality in Tuberculous Meningitis. Clin Infect Dis. 2018; 66(4): 523–32. PubMed Abstract | Publisher Full Text | Free Full Text

3. Kalita J, Misra U, Ranjan P: Predictors of long-term neurological sequelae of tuberculous meningitis: a multivariate analysis. Eur J Neurol. 2007; 14(1): 33–7. PubMed Abstract | Publisher Full Text

4. Saitoh A, Pong A, Waekker NJ Jr, et al.: Prediction of neurologic sequelae in childhood tuberculous meningitis: a review of 20 cases and proposal of a novel scoring system. Pediatr Infect Dis J. 2005; 24(3): 207–12. PubMed Abstract | Publisher Full Text

5. Heemskerk AD, Bang ND, Thwaites GE: Therapy for Tuberculous Meningitis. N Engl J Med. 2016; 374(22): 2188–9. PubMed Abstract | Publisher Full Text

6. Ndyetukira JF, Kwizera R, Kugonza F, et al.: The conundrum of clinical trials and standard of care in sub-Saharan Africa – the research nurse perspective. J Res Nurs. 2019. Publisher Full Text

7. Bahr NC, Nuwagira E, Evans EE, et al.: Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study. Lancet Infect Dis. 2018; 18(1): 68–75. PubMed Abstract | Publisher Full Text | Free Full Text

8. Songkla MN, Tantipong H, Tongsai S, et al.: Lateral Flow Urine Lipoarabinomannan Assay for Diagnosis of Active Tuberculosis in Adults With Human Immunodeficiency Virus Infection: A Prospective Cohort Study. Open Forum Infect Dis. Oxford University Press US. 2019; 6(4): cfz132. PubMed Abstract | Publisher Full Text | Free Full Text

9. Gupta-Weight A, Corbett EL, Wilson D, et al.: Risk score for predicting mortality including urine lipoarabinomannan detection in hospital inpatients with HIV-associated tuberculosis in sub-Saharan Africa: Derivation and external validation cohort study. PLoS Med. 2019; 16(4): e1002776. PubMed Abstract | Publisher Full Text | Free Full Text

10. Gupta-Weight A, Corbett EL, van Oosterhout JJ, et al.: Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial. Lancet. 2018; 392(10144): 292–301. PubMed Abstract | Publisher Full Text | Free Full Text

11. WHO: The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV. Geneva, Switzerland. 2015. Reference Source

12. Bongomin F, Govender NP, Chakrabarti A, et al.: Essential in vitro diagnostics for advanced HIV and serious fungal diseases: international experts’ consensus recommendations. Eur J Clin Microbiol Infect Dis. 2019; 38(9): 1581–1584. PubMed Abstract | Publisher Full Text

13. Bahr NC, Tugume L, Bouware DR: A Word of Caution in Considering the Use of the Lipoarabinomannan Lateral Flow Assay on Cerebrospinal Fluid for Detection of Tuberculous Meningitis. J Clin Microbiol. 2016; 54(1): 241–2. PubMed Abstract | Publisher Full Text | Free Full Text

14. Cox JA, Lukande RL, Kalungi S, et al.: Accuracy of Lipoarabinomannan and Xpert MTB/RIF Testing in Cerebrospinal Fluid To Diagnose Tuberculous Meningitis in an Autopsy Cohort of HIV-Infected Adults. J Clin Microbiol. 2015; 53(8): 2667–73. PubMed Abstract | Publisher Full Text | Free Full Text

15. Cresswell FV, Seebambulide K, Grint D, et al.: High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study) [version 1; peer review: 2 approved]. Wellcome Open Res. 2018; 3: 83. PubMed Abstract | Publisher Full Text | Free Full Text

16. Marais S, Thwaites GE, Schoeman JF, et al.: Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis. 2010; 10(11): 803–12. PubMed Abstract | Publisher Full Text

17. Kwizera R: CSFLAM data set revised. xlsx. figshare.com. 2019. http://www.doi.org/10.6084/m9.figshare.9415853.v1

18. Siddiqi OK, Birbeck GL, Ghebremichael M, et al.: Prospective Cohort Study on Performance of Cerebrospinal Fluid (CSF) Xpert MTB/RIF, CSF Lipoarabinomannan (LAM) Lateral Flow Assay (LFA), and Urine LAM LFA for Diagnosis of Tuberculous Meningitis in Zambian. J Clin Microbiol. 2019; 57(8): e00652-19. PubMed Abstract | Publisher Full Text | Free Full Text

19. Broger T, Sossen B, du Toit E, et al.: Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study. Lancet Infect Dis. 2019; 19(8): 852–61. PubMed Abstract | Publisher Full Text | Free Full Text
Open Peer Review

Current Peer Review Status: ✔ ✔

Version 2

Reviewer Report 02 October 2019
https://doi.org/10.21956/wellcomeopenres.16956.r36606

© 2019 Bonnet M. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Maryline Bonnet
Institute of Research for Development (IRD), Montpellier, France

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Clinical research on tuberculosis.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 16 September 2019
https://doi.org/10.21956/wellcomeopenres.16813.r36425

© 2019 Patel V. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Vinod Patel
Department of Neurology, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal (UKZN), Durban, South Africa

The article is well written with no major flaws.

Regarding the non-TBM category, although 10 patient had cryptococcal meningitis, detail regarding the non-TBM diagnoses is important as this is a control group and a patient without a clinical meningitis may allow for better specificity. I note that some CSF’s were acellular, what were these diagnoses?
Please provide detail (a table with confirmatory findings for TB such as CXR, abdominal ultrasound, scan findings, CSF findings etc.) regarding the aspects considered to arrive at a diagnosis of probable and possible TBM. A similar consideration for possible TBM. This would add clarity on the reliability of the test outcomes.

**Is the work clearly and accurately presented and does it cite the current literature?**
Yes

**Is the study design appropriate and is the work technically sound?**
Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**
Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**
Yes

**Are all the source data underlying the results available to ensure full reproducibility?**
Yes

**Are the conclusions drawn adequately supported by the results?**
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Assessing novel tests in the diagnosis of tuberculous meningitis.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

---

**Author Response 26 Sep 2019**

**Richard Kwizera**, College of Health Sciences, Makerere University, Kampala, Uganda

The article is well written with no major flaws.

**Response:** Thank you.

Regarding the non-TBM category, although 10 patient had cryptococcal meningitis, detail regarding the non-TBM diagnoses is important as this is a control group and a patient without a clinical meningitis may allow for better specificity. I note that some CSF’s were acellular, what were these diagnoses? Please provide detail (a table with confirmatory findings for TB such as CXR, abdominal ultrasound, scan findings, CSF findings etc.) regarding the aspects considered to arrive at a diagnosis of probable and possible TBM. A similar consideration for possible TBM. This would add clarity on the reliability of the test outcomes.

**Response:** A cellular CSF is common in this population with advanced HIV disease even in the setting of a confirmed TB or CM infection (Cresswell, Int J Infect Dis 2018). The not-TBM group scored <6 points on the uniform case definition (n=16) or had a confirmed alternative diagnosis (n=10 with CM).
This manuscript reports the results of a nested study in a large clinical trial, evaluating the accuracy of the CSF LAM for diagnosis of tuberculosis meningitis using both definite TB and composite reference of probable and definite TB based on standard case definitions. The study reports low sensitivity and high specificity and concludes on the modest role of the CSF LAM for diagnosis of TB meningitis. These results are important and the manuscript is well written.

No major comments.

Minor comments:
In the introduction, I suggest the authors adding the recent publication by Siddiqi et al. (2019) in their references.

In Results, I would suggest the authors to present the characteristics of patients with diagnosis of probable TB using the uniform case definitions. I am surprised by the low proportion of probable TB as compared to definite TB. It would be interesting to know the score of patients with probable TB using the uniform case definition criteria. Were cerebral imaging criteria used? It would be also interesting to know the proportion of patients that fit the score of possible TB meningitis using the uniform case definitions. It is indeed important to know the proportion of possible TB meningitis cases based on the uniform cases definitions that were finally classified as non TB meningitis for the accuracy analysis.

It would be interesting to know the proportion of patients with TB positive results from another specimen than CSF, which is also an important criteria for diagnosis of probable TB meningitis. One option could be to present the patients’ characteristics by definite TB, probable TB and others in Table 1.

How do the authors explain that 17% of patients had unknown outcome of death or alive at discharge? It is quite high in a context of a nested study in a clinical trial.

TB culture was not used, which is a limitation of the accuracy analysis. However, Xpert Ultra has a sensitivity that is very close to culture. This could be mentioned as a limitation.

It would be also very interesting to have the results of the urine LAM if used. In the study by Siddiqui et al. the urine LAM had higher sensitivity than the CSF LAM in patients with presumptive TB meningitis.

In the conclusion, the authors could mention the Fuji LAM that is a new LAM POC test that has higher...
sensitivity in urine than the determine LAM POC and should also be evaluated for diagnosis of TB meningitis both in urine and CSF.

References
1. Siddiqi OK, Birbeck GL, Ghebremichael M, Mubanga E, Love S, Buback C, Kosloff B, Ayles H, Atadzhanov M, Dheda K, Koralnik IJ: Prospective Cohort Study on Performance of Cerebrospinal Fluid (CSF) Xpert MTB/RIF, CSF Lipoarabinomannan (LAM) Lateral Flow Assay (LFA), and Urine LAM LFA for Diagnosis of Tuberculous Meningitis in Zambia. J Clin Microbiol. 2019; 57 (8). PubMed Abstract I Publisher Full Text

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Clinical research on tuberculosis.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 26 Sep 2019

Richard Kwizera, College of Health Sciences, Makerere University, Kampala, Uganda

This manuscript reports the results of a nested study in a large clinical trial, evaluating the accuracy of the CSF LAM for diagnosis of tuberculosis meningitis using both definite TB and composite reference of probable and definite TB based on standard case definitions. The study reports low sensitivity and high specificity and concludes on the modest role of the CSF LAM for diagnosis of TB meningitis. These results are important and the manuscript is well written.

Response: Thank you
No major comments.

Minor comments:
Comment: In the introduction, I suggest the authors adding the recent publication by Siddiqi et al
Response: We have now added this suggested reference in the discussion section.

Comment: In Results, I would suggest the authors to present the characteristics of patients with diagnosis of probable TB using the uniform case definitions.
Response: Table 1 has been modified to present the characteristics of patients with diagnosis of definite, probable, possible and not-TBM.

Comment: I am surprised by the low proportion of probable TB as compared to definite TB.
Response: This is likely to be because we used Ultra and not culture or Xpert as the reference standard. We have found Ultra to be better at confirming TBM in our population (Bahr, Lancet ID, 2018)

Comment: Were cerebral imaging criteria used?
Response: Only about 10% (n/N) of the participants had cerebral imaging done as the CT scanner was dysfunctional for part of the study period.

Comment: It would be also interesting to know the proportion of patients that fit the score of possible TB meningitis using the uniform case definitions.
Response: These have been added in Table 1.

Comment: It would be interesting to know the proportion of patients with TB positive results from another specimen than CSF, which is also an important criteria for diagnosis of probable TB meningitis.
Response: 25% of the patients were positive with urine LAM while 20% were positive with urine Ultra.

Comment: One option could be to present the patients’ characteristics by definite TB, probable TB and others in Table 1.
Response: Thank you for this suggestion. This has been done in the modified Table 1.

Comment: How do the authors explain that 17% of patients had unknown outcome of death or alive at discharge? It is quite high in a context of a nested study in a clinical trial.
Response: This study population included patients screened for a clinical trial but only a minority were subsequently enrolled into the trial. We endeavoured to follow screen failures through to hospital discharge but this was not possible in all cases.

Comment: TB culture was not used, which is a limitation of the accuracy analysis. However, Xpert Ultra has a sensitivity that is very close to culture. This could be mentioned as a limitation.
Response: We have found Ultra to be more sensitive than culture (70% versus 43% against definite/probable) for the diagnosis of TBM in our population (Bahr, Lancet ID, 2018). However we agree addition to culture would have been positive so this has been added to the limitations.

Comment: It would be also very interesting to have the results of the urine LAM if used. In the study by Siddiqui et al. the urine LAM had higher sensitivity than the CSF LAM in patients with presumptive TB meningitis.
Response: 25% of the patients were positive with urine TB-LAM LFA (Alere). The details of the urine TB diagnostics are being analysed currently and will be presented separately.
Comment: In the conclusion, the authors could mention the Fuji LAM that is a new LAM POC test that has higher sensitivity in urine than the determine LAM POC and should also be evaluated for diagnosis of TB meningitis both in urine and CSF.

Response: Thank you for this suggestion. This has been added in the conclusion.

Competing Interests: No competing interests were disclosed.